BGC 515
Alternative Names: BGC-515Latest Information Update: 18 Jun 2024
At a glance
- Originator BridGene Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action TEA domain transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haemangioendothelioma; Mesothelioma; Solid tumours
Most Recent Events
- 13 Jun 2024 Phase-I clinical trials in Haemangioendothelioma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06452160)
- 13 Jun 2024 Phase-I clinical trials in Mesothelioma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06452160)
- 13 Jun 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT06452160)